MCAM and prostate carcinoma: Since MCAM has a positive effect on cancer metastasis, studies have demonstrated that MCAM knockdown can reduce lytic bone metastasis in preclinical mouse models of prostate cancer, and MCAM-targeted mAbs can effectively postpone intraosseous metastatic lesions (Zoni et al., 2019).